TABLE 2.

Characteristics of ADR reports of Enfortumab vedotin and Erdafitinib.

	Enfortumab vedotin	Erdafitinib
Number of ADR reports	2,257	1181
Female	526 (23.3%)	333 (28.2%)
Male	1665 (73.8%)	548 (46.4%)
Unknown	66 (2.9%)	300 (25.4%)
<18	0 (0%)	20 (1.7%)
18–44	25 (1.1%)	32 (2.7%)
45–64	353 (15.6%)	125 (10.6%)
65–74	574 (25.4%)	155 (13.1%)
≥75	457 (20.2%)	120 (10.2%)
Unknown	848 (37.6%)	729 (61.7%)
Africa	1 (0.1%)	33 (2.8%)
Americas	1154 (51.1%)	698 (59.1%)
Asia	70 (3.1%)	38 (3.2%)
Europe	1007 (44.6%)	409 (34.6%)
Oceania	25 (1.1%)	3 (0.3%)
2024	624 (27.6%)	180 (15.2%)
2023	709 (31.4%)	287 (24.3%)
2022	423 (18.7%)	267 (22.6%)
2021	310 (13.7%)	230 (19.5%)
2020	289 (8.4%)	176 (14.9%)
2019	1 (0.1%)	39 (3.3%)
2018	1 (0.1%)	2 (0.2%)